Stocks
MoonLake Readies FDA Filing for Skin Treatment Sonelokimab
MoonLake Immunotherapeutics (MLTX) reported strong one-year Phase 3 trial results for sonelokimab in hidradenitis suppurativa, planning a U.S. FDA filing this fall.
MoonLake Immunotherapeutics (MLTX) reported strong one-year Phase 3 trial results for sonelokimab in hidradenitis suppurativa, planning a U.S. FDA filing this fall.